High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity

Pediatric Nephrology

Volumn 20, Issue 12, 2005, Pages 1744-1749

  Ohtomo, Yoshiyuki ^a,b   Fujinaga, Shu ichiro ^a,b   Takada, Masaru ^a   Murakami, Hitohiko ^a   Akashi, Shunji ^a   Shimizu, Toshiaki ^b   Kaneko, Kazunari ^c   Yamashiro, Yuichiro ^b  

^a SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cyclosporin nephropathy; Frequen trelapsing steroid dependent nephrotic syndrome; Mizoribine

Indexed keywords

ACICLOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MIZORIBINE; PREDNISOLONE; STEROID;

ADOLESCENT; ADULT; ARTICLE; ATROPHY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; HUMAN TISSUE; KIDNEY FIBROSIS; KIDNEY TUBULE DISORDER; LONG TERM CARE; MALE; NEPHROTIC SYNDROME; NEPHROTOXICITY; ONSET AGE; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; STEROID THERAPY;

ADOLESCENT; ADULT; AGE OF ONSET; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; JAPAN; MALE; NEPHROSIS, LIPOID; NEPHROTIC SYNDROME; RECURRENCE; RIBONUCLEOSIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 28444481315     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-005-2025-3     Document Type: Article

References (28)

1. International Study of Kidney Disease in Children (1978) Nephrotic syndrome in children: Prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 13:159-165 713276
2. Clark AG, Barratt TM (1999) Steroid-responsive nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE (eds) Pediatric Nephrology, 4th edn. Lippincott, Baltimore, pp 731-747
3. Durkan AM, Hodson EM, Willis NS, Craig JC (2001) Immunosuppressive agents in childhood nephrotic syndrome: A meta-analysis of randomized controlled trials. Kidney Int 59:1919-1927 10.1046/ j.1523-1755.2001.0590051919.x
4. Hulton SA, Dillion MJ, Barratt TM (1994) Long-term cyclosporin therapy in minimal change nephrotic syndrome of childhood. Pediatr Nephrol 8:401-403 10.1007/BF00856511
5. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J (2002) Evaluation and management of proteinuria and nephrotic syndrome in children: Recommendations from a pediatric nephrology panel established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE). Pediatrics 105:1242-1249 10.1542/peds.105.6.1242
6. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61:1029-1037 8623181
7. Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB (2003) Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 18:833-837 10.1007/s00467-003-1175-4
8. Gellermann J, Querfeld U (2004) Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 19:101-104 10.1007/ s00467-003-1300-4
9. Pankiewicz KW, Patterson SE, Black PL, Jayaram HN, Risal D, Goldstein BM, Stuyver LJ, Schinazi RF (2004) Cofactor mimics as selective inhibitors of NAD-dependent inosine monophosphate dehydrogenase (IMPDH) - the major therapeutic target. Curr Med Chem 11:887-900 10.2174/ 0929867043455648
10. Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Ito E, Waga S (2003) Mizoribine oral therapy for patients with disease flare of lupus nephritis. Clin Nephrol 60:390-394 14690255
11. Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34:571-590 3588043
12. Hager PW, Collart FR, Huberman E, Mitchell BS (1995) Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol 49:1323-1329 10.1016/0006-2952(95)00026-V
13. Ishikawa H (1999) Mizoribine and mycophenolate mofetil. Curr Med Chem 6:575-597 10390602
14. Kamata K, Okubo M, Ishigamori E, Masaki Y, Uchida H, Watanabe K, Kashiwagi N (1983) Immunosuppressive effect of bredinin on cell-mediated and humoral immune reactions in experimental animals. Transplantation 35:144-149 6829074
15. Dayton JS, Turka LA, Thompson CB, Mitchell BS (1992) Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 41:671-676 1569921
16. Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS (1991) Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine J Clin Invest 87:940-948
17. Tsuzuki K (2002) Role of mizoribine in renal transplantation. Pediatr Int 44:224-231 10.1046/j.1328-8067.2001.01531.x
18. Hamasaki T, Mori M, Kinoshita Y, Saeki T, Sakano T (1997) Mizoribine in steroid-dependent nephrotic syndrome of childhood. Pediatr Nephrol 11:625-627 10.1007/s004670050351
19. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, Tanizawa T, Wada H, Maki S, for the Pediatric Mizoribine Study Group in Japan (2000) A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 58:317-324 10.1046/j.1523-1755.2000.00168.x
20. Honda M (2002) Nephrotic syndrome and mizoribine in children. Pediatr Int 44:210-216 10.1046/j.1328-8067.2001.01533.x
21. Bagga A, Hari P, Moudgil A, Jordan SC (2003) Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 42:1114-1120 10.1053/j.ajkd.2003.08.011
22. Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB (2003) Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 18:833-837 10.1007/s00467-003-1175-4
23. Gellermann J, Querfeld U (2004) Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 19:101-104 10.1007/ s00467-003-1300-4
24. Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H, Teraoka S, Toma H, Ota K (1996) Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc 28:2643-3648
25. Koshikawa S, Sato M, Narita M, Sakai O, Nakajima M (1993) Clinical evaluation of an immunosuppressive drug, mizoribine (HE-69) on steroid-resistant nephrotic syndrome: A multicenter double-blind comparison study with placebo (in Japanese). Jin To Tohseki 34:631-650
26. Yumura W, Uchida K, Kawashima A, Kobayashi H, Miwa N, Honda K, Nitta K, Nihei H (1999) Evaluation of plasma concentration of mizoribine as an immunosuppressive agent in lupus nephritis patients (in Japanese). Jin To Tohseki 47:705-708
27. Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H (2000) Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun 274:87-92 10.1006/ bbrc.2000.3104
28. Kawasaki Y, Suzuki J, Takahashi A, Isome M, Nozawa R, Suzuki H (2005) Mizoribine oral pulse therapy for steroid-dependent nephrotic syndrome. Pediatr Nephrol 20:96-98 10.1007/s00467-004-1647-1